Protalix BioTherapeutics (NYSE:PLX) Lowered to Buy Rating by StockNews.com

StockNews.com lowered shares of Protalix BioTherapeutics (NYSE:PLX) from a strong-buy rating to a buy rating in a research note published on Friday morning.

Protalix BioTherapeutics Trading Down 2.8 %

NYSE PLX opened at $2.46 on Friday. The company has a 50 day moving average of $1.91 and a 200-day moving average of $1.37. Protalix BioTherapeutics has a 1-year low of $0.82 and a 1-year high of $2.54.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of PLX. PFG Investments LLC bought a new position in Protalix BioTherapeutics in the 4th quarter valued at about $39,000. Cubist Systematic Strategies LLC acquired a new stake in shares of Protalix BioTherapeutics during the 2nd quarter worth approximately $37,000. GSA Capital Partners LLP increased its stake in Protalix BioTherapeutics by 8.5% in the third quarter. GSA Capital Partners LLP now owns 435,213 shares of the company’s stock valued at $444,000 after acquiring an additional 33,969 shares during the last quarter. XTX Topco Ltd bought a new position in Protalix BioTherapeutics in the third quarter valued at approximately $36,000. Finally, Sanctuary Advisors LLC acquired a new position in Protalix BioTherapeutics during the third quarter valued at approximately $38,000. Institutional investors own 16.53% of the company’s stock.

Protalix BioTherapeutics Company Profile

Protalix BioTherapeutics, Inc, a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally.